Resumen

Medullary thyroid carcinoma occurring either sporadically or in the context of Type 2A multiple endocrine neoplasia can follow a relatively indolent and asymptomatic course over many years, including some cases with metastatic disease. Although treatment with the recently approved tyrosine-kinase inhibitors is an option, the decision to indicate them should weight the potential benefits against the potential adverse events of these costly targeted therapies with consideration of the patient’s wishes.

Palabras clave: Medullary thyroid carcinoma type 2A multiple endocrine neoplasia pheochromocytoma RET protooncogene tyrosinekinase inhibitors.

2018-01-03   |   224 visitas   |   Evalua este artículo 0 valoraciones

Vol. 4 Núm.3. Julio-Septiembre 2017 Pags. 150-154 Rev Mex Endocrinol Metabol Nut 2017; 4(3)